News

Polymyositis and dermatomyositis are rare inflammatory myopathies that cause inflammation and progressive weakness in muscles. As part of the deal, the two firms will develop educational programs and

The company said that data from its pilot phase IIa efficacy study in adult ADHD showed efficacy in a range similar to stimulants. The new trial will assess

The new JV company will be used for acquiring, financing, building, owning and operating medical cannabis facilities, including dispensaries and growing operations, throughout Canada. According to the company,

The company’s SNAP technology provides a simple, chemically-driven method for linking any anti-cancer antibody and small molecule cytotoxic drug to produce ADC products with optimal and uniform ratios

ProStrakan has now purchased the entire share capital of Archimedes for a consideration of £230 million in cash. Archimedes is a fast growing European-based specialty pharmaceutical company providing

The trial was conducted in the United States under a Food and Drug Administration Investigational New Drug protocol. The prospective, randomized, double-blind, placebo controlled study in patients with

The current suite supports the processing of ADVATE [Antihemophilic Factor (Recombinant)], the market leading full-length recombinant factor VIII (rFVIII) worldwide for the treatment of patients with hemophilia A.

The product name change from Lomustine (CCNU) to Gleostine represents the company’s strategic initiative to re-launch and re-brand its product pipeline of matured and innovative drugs. The new

Previous studies had demonstrated that VeloThrax also possesses enhanced thermostability, enabling distribution without cold chain requirements. VeloThrax is the Company’s proprietary DNI (dominant negative inhibitor) anthrax rPA (recombinant